ClinicalTrials.gg
CompletedNCT05801627Updated Apr 6, 2023

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin

A Phase 3 interventional study of SAL067 and Placebo in Diabetes Mellitus, Type 2, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-06.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled May 2020, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
216th of 767
408 · median 199
Started
2020
with 49 others
Phase 3
207 of 909
38 open now
Registered
580th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 216th largest by enrollment of the 767 interventional ones that give a count, is one of 50 that started in 2020, is one of 207 in phase 3, and was the 580th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This is the phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in T2DM patients uncontrolled by metformin, comprising 24 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 52 weeks.

Read the detailed description

All eligible subjects would enter the 24 weeks of double-blind treatment period and were randomized into the SAL067 group (12 mg once daily) or placebo group at a 2:1:1 ratio. After 24 weeks of double-blind treatment, subjects would enter the extended open-label treatment period. Subjects in the placebo group were to be switched to SAL067 (12 mg once daily) treatment, while patients in the SAL067 groups continued the same treatment until the end of the whole 52 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetes patients who meet the diagnostic criteria for diabetes issued by the World Health Organization (WHO) in 1999;
  2. Men or women aged 18 to 75 years old at the day of signing the ;
  3. : BMI 19kg/m2 to 35kg/m2, [BMI=weight (kg)/height 2 (m2)];
  4. Subjects treated with metformin≥ 1500mg/day constantly for at least 8 consecutive weeks before screnning;
  5. (HbA1c): Screening period: HbA1c 7.5% to 10.5% (tested by the research center), when randomly enrolled: HbA1c 7.0% to 10.0% (central laboratory test) Measurement);
  6. Screening period and random time fasting blood glucose \<=13.9mmol/L.

Exclusion criteria

Exclusion Criteria:

  1. Drug compliance during the introduction period \<80% or >120%;
  2. Use other hypoglycemic drugs other than test drugs during the introduction period;
  3. The patient may have any , allergies or to fuglitagliptin (including study drug and placebo) or its , DPP4 drugs, metformin;
  4. Before screening, have any of the following endocrine-related medical history or evidence:

    • Diabetes other than type 2 diabetes, such as type 1 diabetes, single-gene mutation diabetes, diabetes caused by pancreatic injury or secondary diabetes, such as diabetes caused by Cushing's syndrome or acromegaly;
    • diabetic ketoacidosis, hyperglycemia and hyperosmolarity, lacticacidosis and other acute complications of diabetes within 6 months before screening;
    • severe hypoglycemia episodes (such as sleepiness caused by hypoglycemia, unconsciousness, nonsense, and even coma), or a serious history of unconscious hypoglycemia;
  5. Before screening, there is a history or evidence of any of the following diseases:

    • Unstable angina, stroke or , myocardial infarction, coronary artery bypass graft or percutaneous coronary intervention (diagnostic angiography is allowed of);
    • Decompensated heart failure before screening ( NYHA heart function grades III and IV, persistent and arrhythmia;
    • A history of acute and chronic pancreatitis, symptomatic gallbladder disease or history of pancreatic injury, etc. may lead to high risk factors for pancreatitis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    SAL067

    SAL067 12mg once daily

    Drug: SAL067

  • Placebo comparator
    Placebo

    placebo once daily

    Drug: Placebo

Interventions

  • DrugSAL067

    SAL067 6mg(2 tablet) and Metformin ≥1500mg

    Also known as: SAL067 Group

  • DrugPlacebo

    Placebo (2 tablet) and Metformin ≥1500mg

    Also known as: Placebo Group

06

What researchers measure

Primary outcomes

  1. HbA1c change from baseline at week 24

    Change From Baseline in Hemoglobin A1c (HbA1c) at week 24

    Time frame: Baseline and week 24

Secondary outcomes

  1. HbA1c change from baseline at week 4,week 12,week 40 and week 52

    Change From Baseline in Hemoglobin A1c (HbA1c) at week 4,week 12,week 40 and week 52

    Time frame: Baseline, week 4, week 12, week 40 and week 52

  2. FPG change from baseline at week 4, week 8, week 12, week 16, week 24, week 40 and week 52

    Time frame: Baseline, week 4, week 8, week 12, week 24, week 40 and week 52

  3. Percentage of patients with HbA1c <7.0% and HbA1c <6.5% at week 24 and week 52

    Time frame: Baseline, week 24 and week 52

  4. Percentage of patients required use of rescue therapy at week 24 and week 52

    Time frame: Baseline, week 24 and week 52

  5. Fasting c-peptide change from baseline at week 24 and week 52

    Time frame: Baseline, week 24 and week 52

  6. Insulin sensitivity change (calculated by HOMA-IS) from baseline at week 24 and week 52

    Time frame: Baseline, week 24 and week 52

  7. eatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52

    Time frame: Baseline, week 24 and week 52

07

Study locations

1 site
  • Peking University Hospital
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in May 2022, 24 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Apr 6, 2023
StartActual
May 6, 2020
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2022
Last update
Apr 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05801627
Responsible party
Sponsor
First posted
Apr 6, 2023
Start date
May 6, 2020
Primary completion
May 24, 2022
Completion
May 24, 2022
Last update
Apr 6, 2023

Study contacts

Xiaohui Guo, Ph.D
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAL067

Start the discussion